Increasing Adherence to Lung Cancer Screening

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Apr 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at ways to help patients stick to their lung cancer screening schedules. The researchers want to see if certain reminders or "nudges" given to both patients and their doctors can encourage more people to get screened and follow up on any necessary tests. The trial is currently recruiting participants, including both primary care doctors and eligible patients who fit specific guidelines.

To be eligible, patients should be between the ages of 50 and 80, have a history of smoking, and have completed a lung cancer screening in the last few years without being diagnosed with lung cancer. If you join the study, you might also be asked to share your thoughts in an interview or survey after the trial to help researchers understand what helps or hinders people from following through with screenings. This study aims to improve lung cancer screening rates, which can lead to earlier detection and better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Clinicians will be eligible if they:
• • 1. are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System;
• • 2. care for patients who completed LCS via LDCT in 2019-2023; and
• • 3. do not opt-out of study participation.
• Patients will be eligible if they:
• • 1. are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years)
• • 2. completed LCS via LDCT in 2019-2023;
• • 3. have not been diagnosed with lung cancer;
• • 4. meet criteria for non-adherence;
• • 5. remain eligible for LCS during the trial enrollment period; and
• • 6. receive LCS care from a clinician that has not opted-out of study participation
• Exclusion Criteria:
• Patients will be excluded if they:
• • a) have a highly suspicious baseline LDCT (Lung-RADS 4B/X) given the presence of existing clinical pathways to ensure adherence in this group